Finding studies
Finding studies
Take this into the appointment.
Saves the questions and what to expect into your notes, next to the visit they belong to.
Lead
Otsuka Pharmaceutical Development & Commercialization, Inc.
This is a multi center, randomized, double-blinded, stratified, placebo-controlled clinical trial in three parallel groups. Participants will be randomized to one of the following three treatment groups: * OBR plus 100 mg OPC-67683 BID * OBR plus 200 mg OPC-67683 BID * OBR plus placebo BID The three treatment groups will comprise approximately 140 participants each (male or female). The trial will consist of the following periods: * Pre-treatment Period (Visits 1 to 3 \[Day -9 to Day -1\]) * Treatment Period (Visits 4 to 59 \[Days 1 to 56\]) * Post-treatment Period (Visits 60 to 64 \[Days 57 to 84\]) Enrolled participants (those accepted into the screening period of the trial who signed an informed consent form) will be stratified at randomization by extent of pulmonary TB; an equal number of participants with and without cavities visible in the lung fields on baseline chest radiograph will be allocated to each treatment group. A total of approximately 430 male or female participants aged 18 to 64 years, inclusive, with pulmonary, sputum culture-positive MDR TB (TB caused by Mycobacterium tuberculosis strains resistant to at least isoniazid and rifampicin) or with sputum smears positive for acid fast bacilli (AFB) and a positive rapid test for rifampicin resistance on direct sputum within 60 days prior to the expected date of enrollment. Participants with positive AFB smears and a positive rapid rifampicin resistance test will be enrolled as presumptively culture positive and withdrawn as ineligible if they are confirmed to not have sputum culture positive MDR TB.
Age
18–64
Sex
ALL
Healthy volunteers
Not accepted
